McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.
Is McKesson (MCK) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.
McKesson (MCK) Misses on Earnings and Sales in Q1
by Zacks Equity Research
McKesson???s adjusted earnings of $2.46 per share missed the Zacks Consensus Estimate of $2.81 and decreased from $3.15 in the year-ago quarter.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
On Jul 10, we issued an updated research report on Chesterbrook, PA-based AmerisourceBergen Corporation (ABC).
Should Value Investors Consider McKesson (MCK) Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Why Is McKesson (MCK) Up 13% Since the Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson (MCK) Up 7.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson Corporation: Should Value Investors Pick this Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal
by Zacks Equity Research
McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.
McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
McKesson Corporation (MCK), one of the largest healthcare services providers, is scheduled to report third-quarter fiscal 2017 results on Jan 25.
McKesson (MCK) to Pay $150 Million to Department of Justice
by Zacks Equity Research
McKesson (MCK) has finalized to resolve U.S. Drug Enforcement Administration and Department of Justice potential federal civil and administrative claims.
McKesson (MCK) Closes Rexall Health Acquisition in Canada
by Zacks Equity Research
McKesson Corporation (MCK) announced that it has completed the acquisition of Canada-based Rexall Health for $2.1 billion
A Whole Lot of Nothing
by Sheraz Mian
Stocks haven't done much lately and the trend will likely continue for some time.
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
by Sheraz Mian
Today's must-read reports are for AbbVie (ABBV), Morgan Stanley (MS) and Union Pacific (UNP).
Where Do We Go From Here?
by Sheraz Mian
The post-Brexit rally has taken many by surprise, but it does beg the question of where we go from here.
Top 6 Research Reports for July 7, 2016
by Sheraz Mian
Today's must-read reports are for Expedia (EXPE), BP (BP) and McKesson (MCK).
Top 6 Research Reports for June 30, 2016
by Sheraz Mian
Today's must-read reports are for Alphabet (GOOGL), Monsanto (MON) and McKesson (MCK).
Top 3 MedTech Stocks Poised to Gain this Earnings Season
by Zacks Equity Research
A bipartisan group of ten senators signed on a bill to repeal the 2.3% federal excise tax on medical device makers.